Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Notes Payables (2016 - 2019)

Lineage Cell Therapeutics' Notes Payables history spans 5 years, with the latest figure at $18000.0 for Q1 2019.

  • For Q1 2019, Notes Payables fell 85.0% year-over-year to $18000.0; the TTM value through Mar 2019 reached $18000.0, down 85.0%, while the annual FY2018 figure was $70000.0, 53.95% down from the prior year.
  • Notes Payables reached $18000.0 in Q1 2019 per LCTX's latest filing, down from $70000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $2.6 million in Q2 2017 to a low of $13000.0 in Q3 2017.
  • Average Notes Payables over 5 years is $375933.3, with a median of $95000.0 recorded in 2015.
  • Peak YoY movement for Notes Payables: surged 2589.47% in 2017, then plummeted 95.3% in 2018.
  • A 5-year view of Notes Payables shows it stood at $95000.0 in 2015, then skyrocketed by 776.84% to $833000.0 in 2016, then tumbled by 81.75% to $152000.0 in 2017, then tumbled by 53.95% to $70000.0 in 2018, then tumbled by 74.29% to $18000.0 in 2019.
  • Per Business Quant, the three most recent readings for LCTX's Notes Payables are $18000.0 (Q1 2019), $70000.0 (Q4 2018), and $70000.0 (Q3 2018).